Attralus Closes $56 Million Financing
February 06, 2024 07:00 ET
|
Attralus, Inc
Attralus, Inc. today announced that it has closed a $56 million financing.
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)
November 07, 2023 07:00 ET
|
Attralus, Inc
124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies.124I-evuzamitide detects multiple types of systemic...
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology
October 02, 2023 07:00 ET
|
Attralus, Inc
Attralus announced eight data presentations related to the use of 124I-evuzamitide (AT-01), the company's pan-amyloid binding imaging agent, at ASNC 2023.
Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
April 03, 2023 07:00 ET
|
Attralus, Inc
AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis
December 19, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
November 17, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate
October 17, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent
September 12, 2022 07:00 ET
|
Attralus, Inc
AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy)AT-01 demonstrates significantly higher left ventricular uptake...
Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis
September 08, 2022 07:00 ET
|
Attralus, Inc
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organsSensitivity in those with previously diagnosed cardiac disease was 100%...
Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
September 07, 2022 07:00 ET
|
Attralus, Inc
AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosisAT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer's ...